The Conversation (0)
Equities.com reported that Lexicon Pharmaceuticals (NASDAQ:LXRX) rose on Tuesday after the company announced its oral diabetes drug LX4211 met its primary endpoints in mid-stage clinical trial of Type 2 diabetes patients with stage 3 or stage 4 kidney disease.
Equities.com reported that Lexicon Pharmaceuticals (NASDAQ:LXRX) rose on Tuesday after the company announced its oral diabetes drug LX4211 met its primary endpoints in mid-stage clinical trial of Type 2 diabetes patients with stage 3 or stage 4 kidney disease.
As quoted in the market news:
In the more than 245 million Type 2 diabetes patients worldwide, insulin production is either low or inefficient in regulating blood glucose levels, which can lead to severe complications, including kidney failure, heart disease and stroke. Hemoglobin A1c level, a measure of glucose in the blood over time, is widely considered the “gold standard” in diabetes control.